Grünwald, Viktor

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 3,019

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Grünwald, V., Gillessen, S., & Horwich, A. (2019) · Annals of Oncology

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 1,151

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., et al. (2019) · The Lancet Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 775

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Tannir, N. M., Albigès, L., McDermott, D. F., Burotto, M., Choueiri, T. K., Hammers, H. J., Barthélémy, P., Plimack, E. R., Porta, C., George, S., et al. (2024) · Annals of Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 231

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., et al. (2020) · Journal for ImmunoTherapy of Cancer

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 224

Exploring membranous NECTIN‐4 expression patterns and enfortumab vedotin response in prostate cancer

Weiten, R., Bernhardt, M., Niemann, M., Kristiansen, G., Grünwald, V., Ritter, M., Hölzel, M., Eckstein, M., Alajati, A., Klümper, N., et al. (2024) · Journal of Cellular and Molecular Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 12